No single drug is universally the “safest” for psoriatic arthritis, because safety depends on your age, other health conditions, and which symptoms need treating. But when researchers compare serious infection rates and other major risks across drug classes, IL-23 inhibitors and a mild oral option called apremilast consistently show the lowest rates of serious side effects. Current guidelines, however, recommend TNF inhibitors as the first-line treatment for most people, balancing both effectiveness and safety.
Understanding the tradeoffs between drug classes can help you have a more informed conversation about which option fits your situation.
How Drug Classes Compare on Serious Infections
Serious infections are one of the most important safety measures for any drug that dials down the immune system. A large meta-analysis published in RMD Open pooled data from clinical trials and real-world studies to calculate infection rates for each drug class used in psoriatic arthritis. The results, measured as infections per 100 patient-years, give a useful side-by-side picture:
- IL-23 inhibitors (and IL-12/23 inhibitors): 0.29 serious infections per 100 patient-years, the lowest of any biologic class
- Apremilast (a PDE4 inhibitor): 0.38 per 100 patient-years
- IL-17 inhibitors: 0.97 per 100 patient-years
- TNF inhibitors: 1.36 per 100 patient-years
- JAK inhibitors: 1.51 per 100 patient-years
IL-23 inhibitors and apremilast had the lowest serious infection rates of any drug class studied. That gap is meaningful: the TNF inhibitor rate was roughly four to five times higher than the IL-23 inhibitor rate. IL-17 inhibitors fell in the middle, with a rate about three times that of IL-23 inhibitors but lower than TNF inhibitors.
IL-23 Inhibitors: Lowest Infection Risk
IL-23 inhibitors work by blocking a very specific immune signaling protein involved in driving psoriatic inflammation. Because they target a narrow part of the immune system rather than broadly suppressing it, they leave more of your immune defense intact. This selectivity is likely why their serious infection rates are so low.
These drugs are given as injections, typically every two to three months after an initial loading period. The infrequent dosing schedule is a practical advantage. The main limitation is that IL-23 inhibitors may not be as effective for certain symptoms, particularly spinal inflammation. If your psoriatic arthritis primarily involves your spine, your doctor may lean toward a different class. They’re also newer to the psoriatic arthritis space than TNF inhibitors, so the long-term safety data, while reassuring so far, covers a shorter time window.
Apremilast: Mildest Oral Option
Apremilast is an oral pill taken twice daily that works differently from biologics. Rather than blocking a specific immune protein, it reduces inflammation by inhibiting an enzyme inside immune cells. It does not suppress the immune system the way biologics or methotrexate do, which is why its serious infection rate is so low.
The tradeoff is potency. Apremilast is generally less effective than biologics for moderate to severe joint disease. It tends to work best for people with milder arthritis or predominantly skin symptoms. Its main downsides are gastrointestinal: diarrhea is the most commonly reported side effect, followed by nausea and abdominal discomfort. These symptoms are most common in the first few weeks and often improve, but they can be significant enough that some people stop the medication. Cardiac safety data for apremilast has been reassuring.
If you have mild psoriatic arthritis and want to avoid injections and immune suppression, apremilast offers the gentlest safety profile of any oral option.
TNF Inhibitors: The Recommended First Choice
Despite not having the lowest infection rate, TNF inhibitors remain the first-line recommendation from the American College of Rheumatology and the National Psoriasis Foundation. This reflects decades of real-world experience and strong evidence that they control joint damage, skin disease, and spinal symptoms effectively.
Their safety record is well understood. The serious infection rate of 1.36 per 100 patient-years is higher than IL-23 inhibitors but still relatively low in absolute terms. Known risks include reactivation of tuberculosis (which is why you’ll be screened before starting), and a modestly increased susceptibility to certain infections. For most otherwise healthy adults, these risks are manageable and well-characterized, which is itself a form of safety: doctors know exactly what to watch for.
JAK Inhibitors Carry Extra Warnings
JAK inhibitors are oral pills that broadly dampen immune signaling. They’re effective, but they carry the most significant safety concerns of any psoriatic arthritis drug class. The FDA requires a boxed warning on these medications after a large safety trial comparing one JAK inhibitor to TNF inhibitors found increased risks across several categories.
Compared to TNF inhibitors, the JAK inhibitor showed a 33% higher rate of major cardiovascular events like heart attacks and strokes, and a 48% higher rate of cancers (excluding non-melanoma skin cancer). The trial also found increased risks of blood clots and death, with evidence that higher doses carried greater risk. These findings led the FDA to restrict JAK inhibitors to patients who haven’t responded to or can’t tolerate TNF inhibitors.
The people most at risk were those over 50 with at least one cardiovascular risk factor, which describes a large portion of psoriatic arthritis patients. If you’re in that group, JAK inhibitors are typically not a first or second choice.
Methotrexate: Familiar but Not Without Risk
Methotrexate has been used for decades and is one of the least expensive options. It’s taken weekly, usually as a pill or injection. The most common lab concern is liver enzyme elevations, which are typically mild and reversible. Recent meta-analyses show that while elevated liver enzymes are common in people taking methotrexate, actual liver damage, fibrosis, or cirrhosis is rare. The medication is stopped if liver enzymes rise above three times the normal limit.
Other side effects include nausea, fatigue, and mouth sores. Regular blood monitoring is required, usually every few months. Despite its long track record, methotrexate has not proven particularly effective for the joint symptoms of psoriatic arthritis in clinical trials, which is one reason guidelines now favor biologics as first-line treatment. Many rheumatologists still use it as an add-on or for patients who primarily have skin involvement.
Safety Considerations for Older Adults
Age changes the safety equation significantly. People over 65 tend to have more conditions like diabetes, high cholesterol, and cardiovascular disease, all of which interact with psoriatic arthritis medications. The natural aging of the immune system (a process called immunosenescence) also means older adults are already more vulnerable to infections and cancers, so drugs that further suppress immunity carry proportionally more risk.
Kidney and liver function decline with age, which affects how the body processes medications. Conventional drugs like methotrexate and cyclosporine tend to be avoided in elderly patients due to higher toxicity. Biologics are generally better tolerated, but the limited research specifically in older populations makes it harder to draw firm conclusions. Among biologics, the narrow immune targeting of IL-23 inhibitors is theoretically advantageous for older adults, though real-world data in this group remains limited. Drug interactions are another concern, since older adults are more likely to be taking multiple medications.
Choosing Based on Your Situation
The safest drug for you depends on which risks matter most given your health profile. A few patterns emerge from the evidence:
- Lowest serious infection risk: IL-23 inhibitors, followed closely by apremilast
- Best option for mild disease without injections: Apremilast, though gastrointestinal side effects are common early on
- Best balance of effectiveness and safety for most people: TNF inhibitors, supported by the longest track record
- Highest safety concerns: JAK inhibitors, due to cardiovascular, cancer, and blood clot risks
Severity matters too. If your arthritis is actively damaging your joints, the safest choice isn’t always the mildest drug. Undertreated psoriatic arthritis causes irreversible joint destruction, and a more potent medication that controls the disease may ultimately be safer than a gentler one that lets damage progress. The goal is matching the right level of treatment to the right level of disease, with the fewest unnecessary risks.